Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OraSure Technologies Leads The Charge With 2 Other Promising Penny Stocks

In This Article:

As the U.S. stock market faces a challenging period with major indices like the Dow and S&P 500 on track for their worst week in two years, investors are increasingly seeking opportunities that may offer resilience amid economic uncertainty. Penny stocks, despite their somewhat outdated moniker, continue to represent an intriguing investment area for those interested in smaller or emerging companies with potential upside. By focusing on firms with strong financials and growth potential, investors can uncover promising opportunities among these lesser-known equities.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.80

$6.25M

★★★★★★

Safe Bulkers (NYSE:SB)

$3.80

$390.66M

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$118.07M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.38

$72.19M

★★★★★★

Tuya (NYSE:TUYA)

$3.44

$2.09B

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8791

$79.15M

★★★★★☆

Smith Micro Software (NasdaqCM:SMSI)

$1.21

$21.82M

★★★★★☆

PHX Minerals (NYSE:PHX)

$3.73

$141.3M

★★★★★☆

TETRA Technologies (NYSE:TTI)

$3.28

$448.82M

★★★★☆☆

Click here to see the full list of 750 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

OraSure Technologies

Simply Wall St Financial Health Rating: ★★★★★★

Overview: OraSure Technologies, Inc. offers point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory services globally, with a market cap of $242.43 million.

Operations: The company's revenue is derived from its Diagnostics and Molecular Solutions segment, which generated $185.83 million.

Market Cap: $242.43M

OraSure Technologies, Inc., with a market cap of US$242.43 million, has faced challenges recently, reporting a net loss of US$19.5 million for 2024 compared to a profit the previous year. Despite being unprofitable, it has reduced losses over five years and maintains no debt, offering some financial stability. The company is seeking acquisitions to expand innovation and recently received FDA approval for expanded use of its OraQuick HIV Self-Test. Legal issues have emerged with NOWDiagnostics alleging breach of contract and other violations against OraSure. Analysts expect stock price growth despite current setbacks in earnings performance.

NasdaqGS:OSUR Revenue & Expenses Breakdown as at Mar 2025
NasdaqGS:OSUR Revenue & Expenses Breakdown as at Mar 2025

Taboola.com

Simply Wall St Financial Health Rating: ★★★★★☆